Brand Engagement Network Advances Skye Salud AI Platform to Phase 2 in Mexico Primary Care
BNAI•Brand Engagement Network’s Skye Salud platform, developed with Grupo Skye and KNOBLOCH Information Group, has entered Phase 2 clinical evaluation in Mexico’s primary care market after completing Phase 1 rheumatology testing. The expanded trial will assess AI-driven evidence retrieval across Spanish-language primary care scenarios to inform future commercial rollout.
1. Phase 1 Rheumatology Evaluation
Phase 1 testing assessed the platform’s performance across specialty-specific rheumatology cases in a controlled environment, focusing on evidence traceability, response quality, and source transparency. Under guidance of Dr. Ruy Carrasco, the evaluation confirmed accurate, cited AI responses grounded in peer-reviewed literature and clinical guidelines.
2. Phase 2 Primary Care Expansion
Phase 2 will expand the evaluation into primary care use cases across a broader range of clinical topics and physician information needs, incorporating Spanish-language content optimized for Mexico’s healthcare environment. Partner organizations will measure content coverage, usability, and performance metrics to identify future development priorities.
3. Strategic Outlook and Commercialization
The initiative aligns with Brand Engagement Network’s strategy to deliver governed, enterprise-grade AI solutions in regulated industries. Positive trial insights may support potential commercialization agreements and market expansion throughout Mexico and Latin America’s large healthcare sector.
